Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
Portfolio Pulse from Benzinga Insights
Ultragenyx Pharmaceutical (NASDAQ:RARE) received mixed analyst ratings with a recent shift towards a more bullish outlook. The average 12-month price target is now $82.55, up 6.93% from the previous $77.20. Analyst actions include ratings from 'Outperform' to 'Neutral' with price targets ranging from $48.00 to $114.00. The company's financials show a positive revenue trend with a 23.27% growth rate, but it faces challenges with a net margin of -96.7%, ROE of -80.22%, and ROA of -9.03%. Its debt-to-equity ratio of 0.16 indicates lower reliance on debt financing.
April 22, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx Pharmaceutical sees mixed analyst ratings with a bullish trend. The average price target increased to $82.55, indicating positive sentiment. Financial challenges persist despite revenue growth.
The increase in the average price target reflects a positive sentiment among analysts, likely to influence investor perception positively in the short term. However, the company's financial challenges, such as a high net margin of -96.7% and low ROE and ROA, may temper investor enthusiasm. The mixed analyst ratings with a recent shift towards bullish outlooks suggest a cautiously optimistic view on the stock's future performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100